Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

onartuzumab

- PMLiVE

Roche’s spinal muscular atrophy treatment Evrysdi shows continued benefit in children

The progressive neuromuscular disease affects approximately one in every 10,000 babies

- PMLiVE

Roche enters licensing agreement with ALZpath to advance Alzheimer’s blood test

The agreement will leverage ALZpath’s pTau217 antibody and Roche’s Elecsys platform

- PMLiVE

Ipsen and Marengo expand oncology research partnership in deal worth $1.2bn

The new agreement centres around Marengo’s TriSTAR T-cell engager platform

- PMLiVE

Roche’s ALK inhibitor Alecensa granted EC approval to treat early-stage lung cancer

Non-small cell lung cancer represents up to 85% of all lung cancer diagnoses

- PMLiVE

AstraZeneca’s Tagrisso combination receives CHMP recommendation for advanced lung cancer

More than 450,000 people are diagnosed with lung cancer every year in Europe

- PMLiVE

Sanofi shares positive late-stage results for Sarclisa in newly diagnosed multiple myeloma

More than 180,000 new cases of the haematological malignancy are diagnosed globally every year

- PMLiVE

ICR researchers identify new treatment pathway for rare set of childhood brain tumours

Gliomatosis cerebri is a highly aggressive glioma that affects 100 people in the US every year

- PMLiVE

Bristol Myers Squibb’s Breyanzi receives FDA approval for mantle cell lymphoma

The rare form of non-Hodgkin lymphoma accounts for around 3% of all NHL cases

- PMLiVE

Pfizer shares positive five-year results for Lorbrena in advanced lung cancer

The majority of Lorbrena-treated patients were alive without disease progression after five years

- PMLiVE

ICR’s cancer cell study could offer longer-lasting protection for breast cancer patients

The condition affects over 55,000 people in the UK every year

- PMLiVE

The Power of Patient Insights to Improve Cancer Care

Two global patient advocacy groups—The Lymphoma Coalition and Lung Cancer Europe— are compiling data from their communities on the real-world experience of living with cancer. What the data reveals sometimes...

Medscape Education Global

- PMLiVE

Eli Lilly and Aktis enter $1bn partnership to develop anticancer radiopharmaceuticals

Lilly will gain rights to develop Aktis’ lead programme targeting a tumour-associated antigen

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links